Skip to main content
Opens in new window
NHS Wales
NHS 111 Wales
Skip Navigation
Accessibility
Contact us
Cymraeg
Cymraeg
All...
Search
All Wales Therapeutics and Toxicology Centre
Search
Cymraeg
Cymraeg
Menu
Home
Accessing medicines
Medicines optimisation and safety
Show Submenu For Medicines optimisation and safety
Medicines optimisation guidance, resources and data
Yellow Card Centre Wales
Welsh National Poisons Unit
Sodium valproate information hub
Work in progress
News, meetings and events
Show Submenu For News, meetings and events
News
Meetings
Events
About us
Show Submenu For About us
Our committees
Who we are
What we do
Who we work with
Our research
Our reports and strategies
Sustainability
Contact us
More
×
NHS Wales
NHS 111 Wales
Accessibility
Contact us
All...
Search
Listen
Home
›
Accessing medicines
›
One Wales Medicines process
›
One Wales medicine assessment documents
›
OW29 documents
OW29 documents
20/06/2025
Panitumumab supplementary tables CIC removed for website OW29
20/06/2025
Panitumumab rechallenge mCRC ESR CIC removed for website OW29
20/06/2025
Panitumumab RASWT mCRC final recommendation with start_stop criteria (OW29)
20/06/2025
OWMAG decision rationale panitumumab mCRC final OW29
20/06/2025
EqHIA Panitumumab for RASWT mCRC assessment 2025 OW29
20/06/2025
Appendix 2.b. Cost of regorafenib followed by best supportive care and Appendix 2.c. Cost of best supportive care for fifth-line
20/06/2025
Appendix 2.a. Cost of trifluridine-tipiracil and bevacizumab followed by best supportive care
20/06/2025
Appendix 1 PRISMA flow diagram (43)
20/06/2025
Table 13. Budget impact for four months panitumumab as fourth line treatment
20/06/2025
Table 12. Budget impact for four months panitumumab as third line treatment
20/06/2025
Table 11. Net resource costs for upper and lower patient number estimates for panitumumab and comparator treatments
20/06/2025
Table 10. Cost of panitumumab and comparators in Wales (per patient)
20/06/2025
Table 9. Severity modifier considerations for One Wales Medicines Assessment Group (OWMAG)
20/06/2025
Table 8. Examples of medicine acquisition costs
20/06/2025
Table 7. Potential QALY by treatment line
20/06/2025
Table 6. Threshold analysis
20/06/2025
Table 5. Fourth-line and Fifth-line cost consequence analyses
20/06/2025
Table 4. Base case analysis
20/06/2025
Table 3. Progression free survival, overall survival and adverse events
20/06/2025
Table 2. Comparator costs
1
2
Follow AWTTC: